Plasma epidermal growth factor decreased in the early stage of Parkinson's disease

Aging and Disease

Volumn 6, Issue 3, 2015, Pages 168-173

  Jiang, Qian Wen ^a   Wang, Cheng ^a   Zhou, Yi ^a   Hou, Miao Miao ^a   Wang, Xi ^a   Tang, Hui Dong ^a   Wu, Yi Wen ^a   Ma, Jian Fang ^a   Chen, Sheng Di ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor; Essential tremor; Parkinson's disease

Indexed keywords

AMANTADINE; BENSERAZIDE; BIOLOGICAL MARKER; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR; LEVODOPA; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL TREMOR; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; QUESTIONNAIRE;

EID: 84935445991     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14336/AD.2014.0925     Document Type: Article

References (21)

1. Lees AJ, Hardy J, Revesz T (2009). Parkinson's disease. Lancet, 373(9680):2055-2066.
2. Weissmiller AM, Wu C (2012). Current advances in using neurotrophic factors to treat neurodegenerative disorders. Translational neurodegeneration, 1(1):14.
3. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013). GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacology & therapeutics, 138(2):155-175.
4. Gomez-Pinilla F, Knauer DJ, Nieto-Sampedro M (1998). Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular localization. Brain research, 438(1-2):385-390.
5. Iwakura Y, Piao YS, Mizuno M, et al (2005). Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. Journal of neurochemistry, 93(4):974-983.
6. Grainne C.O Keeffe, Pam Tyers, Dag Aarsland et al (2009). Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. PNAS, 106: 8754-8759
7. Pezzoli G, Zecchinelli A, Ricciardi S, et al (1991). Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats. Movement disorders: official journal of the Movement Disorder Society, 6(4):281-287.
8. Chen-Plotkin AS, Hu WT, Siderowf A, et al (2011). Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of neurology, 69(4):655-663.
9. Kuhlenbäumer G, Hopfner F, Deuschl G (2014). Genetics of essential tremor: meta-analysis and review. Neurology, 82(11):1000-7.
10. Delay C, Tremblay C, Brochu E, et al (2014). Increased LINGO1 in the cerebellum of essential tremor patients. Mov Disord. Feb 14. [Epub ahead of print]
11. Inoue H, Lin L, Lee X, et al (2007). Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. PNAS, 104(36):14430-14435.
12. Deuschl G, Bain P, Brin M (1998). Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Movement disorders: official journal of the Movement Disorder Society, 13 Suppl 3:2-23.
13. Chen W, Chen S, Kang WY, et al (2012). Application of odor identification test in Parkinson's disease in China: a matched case-control study. Journal of the neurological sciences, 316(1-2):47-50.
14. Booij J, Tissingh G, Boer GJ, et al (1997). [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 62(2):133-140.
15. Brusa L, Pavino V, Massimetti MC, Bove R, Iani C, Stanzione P (2013). The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. Functional neurology, 28(1):13-17.
16. Babij R, Lee M, Cortes E, Vonsattel JP, Faust PL, Louis ED (2013). Purkinje cell axonal anatomy: quantifying morphometric changes in essential tremor versus control brains. Brain: a journal of neurology, 136(Pt 10):3051-3061.
17. Birecree E, King LE, Jr., Nanney LB (1991). Epidermal growth factor and its receptor in the developing human nervous system. Brain research Developmental brain research, 60(2):145-154.
18. Kuo SH, Tang G, Louis ED, et al (2013). Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta neuropathologica, 125(6):879-889.
19. Zhou ZD, Sathiyamoorthy S, Tan EK (2012). LINGO-1 and Neurodegeneration: Pathophysiologic Clues for Essential Tremor. Tremor and other hyperkinetic movements, 2. pii: tre-02-51-249-1.
20. Pellecchia MT, Santangelo G, Picillo M, et al (2013). Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. Journal of neurology, 260(2):438-444.
21. Rocha NP, Teixeira AL, Scalzo PL, et al (2014). Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society, 29(4):527-31